Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata

Rezafungin (CD101) is a novel echinocandin antifungal agent with activity against Aspergillus and Candida species, including azole- and echinocandin-resistant isolates. The objective of these analyses was to conduct pharmacokinetic (PK)-pharmacodynamic (PD) target attainment analyses to evaluate sin...

Descripción completa

Detalles Bibliográficos
Autores principales: Bader, Justin C., Lakota, Elizabeth A., Flanagan, Shawn, Ong, Voon, Sandison, Taylor, Rubino, Christopher M., Bhavnani, Sujata M., Ambrose, Paul G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2018
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971579/
https://www.ncbi.nlm.nih.gov/pubmed/29555634
http://dx.doi.org/10.1128/AAC.02614-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971579/
https://www.ncbi.nlm.nih.gov/pubmed/29555634
http://dx.doi.org/10.1128/AAC.02614-17

Ejemplares similares